News
HST Collects relevant news from a variety of sources, for your convenience. Select a story from below, or use our search feature to find stories of interest.

Generic anti-AIDS drugs withdrawn from WHO list
PLUSNEWS
2004-11-11

In a move that could affect HIV-positive people on treatment in developing countries, an Indian generic drug manufacturer voluntarily withdrew its drugs from the World Health Organisation's (WHO) list of approved HIV medicines.

The seven antiretroviral (ARV) drugs made by Ranbaxy Laboratories were removed after the company found discrepancies in documents proving their biological equivalence to the patented versions, a WHO statement said. In August this year, WHO withdrew three other drugs made by the company for the same reason.

The impact of Ranbaxy's decision on African countries embarking on treatment initiatives remains unclear.

Of course, we are worried about the disruption of ARV programmes, particularly in developing countries - many have already ordered large quantities of drugs, WHO spokeswoman Daniela Bagozzi told PlusNews.

However, this did not mean there were any real problems with the drugs in terms of safety. The problem was that the medicines may or may not offer the same therapeutic benefits as the originals on which they were based, she noted.

WHO has advised that patients on treatment should discontinue using the de-listed drugs, but recommended that when alternative quality-controlled treatment could not be immediately found, patients should continue on the drug regimen, as interrupting treatment was more dangerous.

According to Bagozzi, the WHO delisting did not bind countries to ban the Ranbaxy products. It was up to individual countries and their drug regulatory authorities to decide whether to continue using the drugs or not.

But countries relying on Global AIDS Fund resources for their treatment programmes would not be able to continue using the drugs, as the Fund has stipulated that only WHO-approved ARVs were to be used.

African treatment programmes funded by the Global Fund and using Ranbaxy drugs are: Benin, Central African Republic, Cote d'Ivoire, Malawi and Swaziland.

Of all the HIV/AIDS grants we've given out, we estimate that about 10 countries are currently using Ranbaxy products, Global Fund spokesman Tim Clark, told PlusNews.

Meanwhile, Ranbaxy's announcement was unlikely to have much of an impact on Medecins Sans Frontieres' (MSF) treatment project in South Africa, as the initiative only used two of their drugs, and these could easily be replaced, Marta Darder, the MSF coordinator for access to essential medicines, told PlusNews.( Source:PLUSNEWS, 10 November 2004).

For more information on the practical implications of the withdrawal of the Ranbaxy drugs from the WHO list:http://mednet3.who.int/

Keywords	This Item is associated with the Following Keywords: .
You Can Comment on this Item, or View other people's Comments
Easy Print  Email to a friend

	Related News
	Generic AIDS drugs to be re-evaluated (2004-08-17) Cheaper generic Aids drugs for SA (2006-02-23) WHO Hurting Cheap AIDS Drugs Industry - Experts (2004-08-17) WHO releases list of recommended AIDS drugs (2002-03-27) WHO removes three Ranbaxy antiretrovirals from prequalification list due to failings in research procedures (2004-08-06)

	Related Publications
	Introducing Antiretroviral Therapy (ART) on a Large Scale: Hope and Caution (2004-03-31) Standard Treatment Guidelines and Essential Drugs List - Primary Health Care 2003 Edition (2004-11-03) Essential Drugs List Programme (2000-06-08) Nothing new: responses to the introduction of antiretroviral drugs in South Africa (2006-09-28) Anti-Retroviral Therapy in South Africa - A pocket guide of the prevention and management of Side Effects and Drug Interactions (2004-10-12)

	Related Health Statistics
	Primary drug of abuse as % of all drugs of abuse (2007-05-21) Percentage of facilities out of stock: STI medicines (2004-05-14) Cure rate (new Sm+ cases) (2005-05-25) Percentage provider knowledge of correct drug treatment of STI syndromes (2004-05-14) Interruption (defaulter) rate (new Sm+ cases) (2005-05-25)

	Related Events
	Training Course on Drug and Therapeutic Committees (2001-10-18) International HIV/AIDS Treatment Education and Advocacy Summit (2000-03-13) SAfAIDS Symposium on Access to Treatment (2003-01-29) International AIDS Society Conference on HIV Pathogenesis and Treatment (2003-07-13) INCLEN Global Meeting XVII - Research Networks in the New Millenium: Developing Countries' Contribut (2000-10-15)

	Related links
	Essential Drugs and Medicines Policy (EDM) Essentialdrugs.org MSF Campaign for Access to Essential Medicines Standard Treatment Guidelines and Essential Drugs List, SA Medicines for Malaria Venture

	Related Content
	Summary Bulletin 10 (August) - DHS-LG Discussion List (2004-07-16) The Treatment Monitor (2004-03-31) Treatment Monitor: Sexual and Reproductive Intentions (2008-02-14) Treatment Monitor: Treatment as part of a continuum of care (2007-07-11) Treatment Monitor: Focus on Human Resources (2008-02-14)